Moderna (MRNA) 10-Q2021 Q3 Quarterly report

Filed: 4 Nov 21, 4:48pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ACIP, adjuvant, African, Arabia, asymptomatic, Australia, carbon, CMVictory, curative, distributor, Domain, downstream, dysfunctional, easier, glucose, GMR, goal, green, ILCM, imbalance, immunocompromised, inhaled, KEYTRUDA, leasehold, melanoma, men, Metagenomi, mg, MSC, muscle, neck, newest, nonprofit, notified, NTD, occupational, parainfluenza, partnership, pathological, proceed, RBD, refined, resected, Saudi, seroresponse, shift, Spikevax, Syndrome, top, underway, vivo

Removed: Aid, ASPR, CABG, Chiesi, collaborative, economy, Farmaceutici, fill, initiated, produced, programmed, relief, return, security, twelve, uncertain

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated MRNA transcripts

MRNA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Moderna, Inc. (the “Company”) for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Stéphane Bancel, Chief Executive Officer of the Company, and David W. Meline, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 4, 2021	By:	/s/ Stéphane Bancel
		Stéphane Bancel
		Chief Executive Officer
		(Principal Executive Officer)

Date: November 4, 2021	By:	/s/ David W. Meline
		David W. Meline
		Chief Financial Officer
		(Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.